Crimean-Congo Hemorrhagic Fever (CCHF) presents a spectrum of clinical manifestations, ranging from asymptomatic cases to severe, life-threatening conditions. Despite extensive research on CCHF pathogenesis, comprehensive understanding remains elusive. Our investigation focused on assessing serum beta 2-microglobulin (β2M) levels in CCHF patients, aiming to elucidate its potential as an immune activation marker and its involvement in disease pathogenesis. The study enrolled 45 CCHF patients and 45 healthy volunteers as a control group. Serum β2M levels were quantified using the immunoturbidimetric analysis method. The patient group was divided into two groups, mild and moderate-severe, using scoring systems. The mean β2M values for the control, mild, and moderate-severe patient groups were 2.27±0.50, 4.37±1.29, and 5.82±2.62 mg/L, respectively (p<0.001). Positive correlations were noted between β2M concentrations and markers such as BUN, creatinine, uric acid, creatine kinase, and aPTT (p<0.001, r=0.684; p<0.001, r=0.602; p=0.003, r=0.439; p=0.008, r=0.392; p=0.019, r=0.348, respectively). Conversely, negative correlations were observed with total protein, albumin, and platelet count (p=0.021, r=-0.342; p=0.003, r=-0.434; p=0.048, r=-0.296, respectively). The findings suggest a prominent inflammatory response in CCHF, indicated by elevated β2M levels, implying its potential role in the molecular mechanisms of the disease
The procedures were approved by the Ethical Committee of Sivas Cumhuriyet University following the ethical standards established by the institution (2021-04/02). All procedures were performed in accordance with the Helsinki Declaration as revised in 2013. Informed consent was obtained from all individuals included in this study.
Primary Language | English |
---|---|
Subjects | Medical Biochemistry - Proteins, Peptides and Proteomics |
Journal Section | Natural Sciences |
Authors | |
Publication Date | June 30, 2024 |
Submission Date | January 19, 2024 |
Acceptance Date | April 19, 2024 |
Published in Issue | Year 2024 |